Drug Delivery via the Suprachoroidal Space for the Treatment of Retinal Diseases

Haim, Liron Naftali Ben; Moisseiev, Elad

doi:10.3390/pharmaceutics13070967

Cited by 38 publications

(32 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The novel drug delivery techniques have facilitated better access to the suprachoroidal space for the treatment of ocular diseases. The drugs administered through the suprachoroidal space allow the attainment of higher concentrations in the retinal region, thereby reducing the undesirable delivery to the anterior ocular areas [ 126 ]. A novel antineoplastic agent called axitinib has a potent blocking activity over VEGF and platelet-derived growth factor (PDGF) receptors, therefore axitinib helps in the neovascularization and treatment of AMD [ 127 ].…”

Section: Novel Drug Delivery Systems For Amdmentioning

confidence: 99%

Novel Approaches in the Drug Development and Delivery Systems for Age-Related Macular Degeneration

Paliwal

Prajapati

Srichana

et al. 2023

Life

View full text Add to dashboard Cite

The number of patients with ocular disorders has increased due to contributing factors such as aging populations, environmental changes, smoking, genetic abnormalities, etc. Age-related macular degeneration (AMD) is one of the common ocular disorders which may advance to loss of vision in severe cases. The advanced form of AMD is classified into two types, dry (non-exudative) and wet (exudative) AMD. Although several therapeutic approaches are explored for the management of AMD, no approved therapy can substantially slow down the progression of dry AMD into the later stages. The focus of researchers in recent times has been engaged in developing targeted therapeutic products to halt the progression and maintain or improve vision in individuals diagnosed with AMD. The delivery of anti-VEGF agents using intravitreal therapy has found some success in managing AMD, and novel formulation approaches have been introduced in various studies to potentiate the efficacy. Some of the novel approaches, such as hydrogel, microspheres, polymeric nanoparticles, liposomes, implants, etc. have been discussed. Apart from this, subretinal, suprachoroidal, and port delivery systems have also been investigated for biologics and gene therapies. The unmet potential of approved therapeutic products has contributed to several patent applications in recent years. This review outlines the current treatment options, outcomes of recent research studies, and patent details around the novel drug delivery approach for the treatment of AMD.

show abstract

Section: Novel Drug Delivery Systems For Amdmentioning

confidence: 99%

Novel Approaches in the Drug Development and Delivery Systems for Age-Related Macular Degeneration

Paliwal

Prajapati

Srichana

et al. 2023

Life

View full text Add to dashboard Cite

show abstract

“…The suprachoroidal space (SCS) has become an applicable route to deliver drugs to the back of the eye via suprachoroidal injection [ 213 ]. When delivered to the suprachoroidal space, the drug can target both the retina and the choroid, overcoming multiple ocular tissue barriers and achieving the efficacy at low dose [ 142 , 214 ].…”

Section: Therapeutic Strategies For Dmementioning

confidence: 99%

Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications

Zhang

Zhang²,

Zhang

et al. 2022

Cells

View full text Add to dashboard Cite

Diabetic retinopathy (DR), with increasing incidence, is the major cause of vision loss and blindness worldwide in working-age adults. Diabetic macular edema (DME) remains the main cause of vision impairment in diabetic patients, with its pathogenesis still not completely elucidated. Vascular endothelial growth factor (VEGF) plays a pivotal role in the pathogenesis of DR and DME. Currently, intravitreal injection of anti-VEGF agents remains as the first-line therapy in DME treatment due to the superior anatomic and functional outcomes. However, some patients do not respond satisfactorily to anti-VEGF injections. More than 30% patients still exist with persistent DME even after regular intravitreal injection for at least 4 injections within 24 weeks, suggesting other pathogenic factors, beyond VEGF, might contribute to the pathogenesis of DME. Recent advances showed nearly all the retinal cells are involved in DR and DME, including breakdown of blood-retinal barrier (BRB), drainage dysfunction of Müller glia and retinal pigment epithelium (RPE), involvement of inflammation, oxidative stress, and neurodegeneration, all complicating the pathogenesis of DME. The profound understanding of the changes in proteomics and metabolomics helps improve the elucidation of the pathogenesis of DR and DME and leads to the identification of novel targets, biomarkers and potential therapeutic strategies for DME treatment. The present review aimed to summarize the current understanding of DME, the involved molecular mechanisms, and the changes in proteomics and metabolomics, thus to propose the potential therapeutic recommendations for personalized treatment of DME.

show abstract

“…The use of a standard hypodermic needle is less invasive, but since there is no visualization, great skill is required in order to achieve precise injection. The most promising method for SCS administration is the use of microneedles whose length are designed to fit the approximate thickness of the sclera and have important advantages: minimally invasive, very good safety profile, simple to use, less painful, inexpensive [78]. In addition to stem cells, PRP was also used by Limoli et al, which is also a source of growth factors and other bioactive molecules that are necessary for wound healing.…”

Section: Clinical Trials Using Stem Cells In Glaucomamentioning

confidence: 99%

The Future of Stem Cells and Their Derivates in the Treatment of Glaucoma. A Critical Point of View

Nicoară

Brie

Jurj

et al. 2021

IJMS

View full text Add to dashboard Cite

This review focuses on the clinical translation of preclinical studies, especially those that have used stem cells in the treatment of glaucoma, with an emphasis on optic nerve regeneration. The studies referred to in the review aim to treat optic nerve atrophy, while cell therapies targeting other sites in the eye, such as the trabecular meshwork, have not been addressed. Such complex and varied pathophysiological mechanisms that lead to glaucoma may explain the fact that although stem cells have a high capacity of neuronal regeneration, the treatments performed did not have the expected results and the promise offered by animal studies was not achieved. By analyzing the facts associated with failure, important lessons are to be learned: the type of stem cells that are used, the route of administration, the selection of patients eligible for these treatments, additional therapies that support stem cells transplantation and their mode of action, methods of avoiding the host’s immune response. Many of these problems could be solved using exosomes (EV), but also miRNA, which allows more targeted approaches with minimal side effects.

show abstract

Drug Delivery via the Suprachoroidal Space for the Treatment of Retinal Diseases

Cited by 38 publications

References 99 publications

Novel Approaches in the Drug Development and Delivery Systems for Age-Related Macular Degeneration

Novel Approaches in the Drug Development and Delivery Systems for Age-Related Macular Degeneration

Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications

The Future of Stem Cells and Their Derivates in the Treatment of Glaucoma. A Critical Point of View

Contact Info

Product

Resources

About